AI-Powered Health Information
⚠ Medical Disclaimer: All content on this site is AI-generated and for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional. Full disclaimer
Medical Research

New FDA-Approved Alzheimer’s Drugs: Eligibility, Real Costs, and Insurance Coverage Explained

Two new FDA-approved Alzheimer’s drugs can slow cognitive decline in early-stage patients, but they come with strict eligibility rules and high price tags. Learn who qualifies, what the real out-of-pocket costs look like, and how Medicare and private insurance handle coverage for these infusions.

Sarah Chen, MD , Board-Certified Neurologist, Health Content Specialist
Published Nov 19, 2026 · Updated Nov 22, 2026
AI-generated, reviewed by AI Auto-Generator

Introduction

Alzheimer’s disease affects over six million Americans, with the Centers for Disease Control and Prevention ranking it as the sixth leading cause of death in the United States. For years, treatment options focused only on managing symptoms like memory loss and mood changes. That landscape shifted dramatically in 2023 and 2024 when the U.S. Food and Drug Administration approved the first two disease-modifying therapies. These medications target the underlying biology of the disease rather than just masking symptoms. Understanding eligibility, real costs, and insurance pathways is essential for patients and families navigating this new treatment era.

Understanding the Two FDA-Approved Disease-Modifying Drugs

Both approved medications are monoclonal antibodies designed to clear amyloid-beta plaques from the brain. Amyloid plaques are sticky protein clusters that build up between nerve cells and disrupt communication. Removing these plaques has been shown in clinical trials to slow cognitive decline by roughly 27 to 35 percent over 18 months. Neither drug cures Alzheimer’s, but they change the disease trajectory when started early.

Leqembi (lecanemab)

Leqembi received full FDA approval in July 2024 after initially gaining accelerated approval in January 2023. It is administered through intravenous infusions every two weeks at a certified infusion center. The Clarity AD clinical trial demonstrated that patients taking Leqembi experienced significantly slower decline on standard cognitive and daily function scales compared to those receiving a placebo. The medication requires patients to have mild cognitive impairment or mild dementia stage Alzheimer’s, confirmed by a positive amyloid PET scan or cerebrospinal fluid test.

Kisunla (donanemab)

Kisunla gained full FDA approval in July 2024. It follows a different dosing schedule, given monthly for the first eight months, then every three months once brain imaging shows plaque levels have dropped below a specific threshold. The TRAILBLAZER-ALZ 2 trial showed that patients who reached the plaque clearance target experienced a 35 percent slower decline over 18 months. Like Leqembi, Kisunla is reserved for early-stage Alzheimer’s and requires confirmed amyloid pathology before treatment begins.

Who Qualifies for These Treatments?

Eligibility is strict because these drugs work best when started before significant nerve cell loss occurs. Neurologists and memory clinic specialists typically evaluate candidates using the following criteria:

  • Stage of Disease: Patients must have mild cognitive impairment or mild dementia due to Alzheimer’s. Symptoms usually include noticeable memory gaps, trouble finding words, or difficulty with familiar tasks, but the patient must still live independently or with minimal assistance.
  • Confirmed Amyloid Pathology: A positive amyloid PET scan or cerebrospinal fluid analysis is mandatory. These tests prove that amyloid plaques are present, which is required for both FDA approval and insurance authorization.
  • Age and Health Status: Most candidates are between 50 and 85 years old. Patients with severe cardiovascular disease, bleeding disorders, or those taking blood thinners may be excluded due to safety monitoring requirements.
  • Ability to Commit to Monitoring: Treatment requires regular MRI scans to check for brain swelling or microbleeds. Patients must live near a certified infusion center and have reliable transportation for visits every two to four weeks.

Real Costs and Out-of-Pocket Expenses

The list prices for these medications are high, but actual patient costs depend heavily on insurance type and clinical trial participation. Understanding the breakdown helps families plan financially.

  • Medication Cost: Leqembi lists at approximately $26,500 per year. Kisunla lists at approximately $32,000 per year. These prices cover the drug itself and do not include infusion fees or monitoring.
  • Infusion Center Fees: Each visit requires intravenous administration, vital sign checks, and post-infusion observation. Out-of-network infusion centers typically charge between $1,500 and $3,000 per visit. Over a year, this adds roughly $15,000 to $20,000 in facility fees.
  • MRI Monitoring: Patients need baseline MRIs before starting treatment, followed by scans every three to six months. A single brain MRI without contrast costs around $800 to $1,500 out-of-pocket. With insurance, copays usually range from $100 to $400 per scan.
  • Total Annual Cost: Without insurance, treatment can exceed $60,000 annually. With commercial insurance, patients often face copays, coinsurance, or deductibles that can still reach $5,000 to $15,000 per year depending on their plan structure.

How Insurance and Medicare Handle Coverage

Insurance coverage for disease-modifying Alzheimer’s drugs has evolved rapidly since FDA approval. The U.S. healthcare system uses different pathways for public and private payers.

Medicare Coverage Rules

The Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination in 2023 that allows Medicare to cover Leqembi and Kisunla, but only under specific conditions. Medicare will fully cover the drug and all associated MRI monitoring if the patient participates in a qualifying clinical trial or receives the medication through a certified research network. Outside of clinical trials, Medicare may cover the drug if a physician documents medical necessity and the patient meets strict diagnostic criteria. Prior authorization is required, and many Medicare Advantage plans require step therapy or formulary exceptions before approving coverage.

Commercial Insurance Pathways

Private insurers like UnitedHealthcare, Aetna, Cigna, and Blue Cross Blue Shield affiliates handle coverage differently. Most require prior authorization, proof of early-stage diagnosis, and a positive amyloid test. Some plans cover the drug but apply high coinsurance percentages, while others restrict coverage to clinical trial participants only. Patients should contact their insurance provider directly to verify formulary status, request a formulary exception if needed, and ask about patient assistance programs offered by the drug manufacturers.

Monitoring and Managing Side Effects

Both medications carry a boxed warning for amyloid-related imaging abnormalities, commonly called ARIA. ARIA involves temporary brain swelling or microbleeds that usually show up on MRI before causing noticeable symptoms. Most cases are mild and resolve on their own, but monitoring is non-negotiable.

  • ARIA Symptoms: Headaches, confusion, dizziness, vision changes, nausea, or rapid thinking decline. These typically appear within the first four to six months of treatment.
  • Monitoring Schedule: Patients receive an MRI before the first dose, then again after the fourth and eighth infusions. If ARIA appears, doctors pause treatment and repeat the MRI until the swelling clears.
  • Infusion Reactions: Nausea, rash, fatigue, or fever can occur during or shortly after the infusion. Infusion centers are equipped to manage these reactions with antihistamines, acetaminophen, or temporary dose adjustments.
  • Long-Term Safety: Clinical trial data shows that ARIA risk decreases after the first year of treatment. Most patients tolerate the medications well once the initial monitoring phase passes.

Key Takeaway: Early detection remains the most powerful tool. Patients who begin treatment during the mild cognitive impairment stage preserve more brain function and experience fewer treatment interruptions than those who wait until symptoms worsen.

Next Steps for Patients and Families

Starting disease-modifying therapy requires coordination between neurologists, imaging specialists, and insurance coordinators. Families should request a comprehensive cognitive evaluation at a certified memory clinic, discuss amyloid testing options, and verify insurance coverage before scheduling the first infusion. Many academic medical centers and large hospital systems now host dedicated infusion clinics for Alzheimer’s treatments, which streamline appointments and reduce travel burden.

Conclusion

The approval of Leqembi and Kisunla marks a turning point in Alzheimer’s care. These medications do not reverse damage, but they slow progression when used correctly in the right patients. Eligibility hinges on early diagnosis, confirmed amyloid pathology, and a commitment to regular MRI monitoring. Costs remain high, but Medicare coverage for clinical trial participants and expanding commercial insurance pathways are making treatment more accessible. Patients who act early, verify insurance details, and partner with certified infusion centers position themselves to maximize the benefits of this new generation of Alzheimer’s therapies.

⚠
Medical Disclaimer — AI-Generated Content This content was created with the assistance of artificial intelligence and is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health decisions. AI-generated content may contain errors or omissions. Read full disclaimer
AI-generated content, reviewed by AI Auto-Generator
Was this helpful?
Sarah Chen, MD , Board-Certified Neurologist, Health Content Specialist

Ask Health.AI about New FDA-Approved Alzheimer’s Drugs: Eligibility, Real Costs, and Insurance Coverage Explained

Get instant answers from our AI health assistant

Hi! I can help answer your questions about New FDA-Approved Alzheimer’s Drugs: Eligibility, Real Costs, and Insurance Coverage Explained. What would you like to know?

AI-Powered Health Information · For informational purposes only — not medical advice
⚠ Medical Disclaimer: All content on this site is AI-generated and for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional. Full disclaimer